Back to Search

ARCT-032 for Cystic Fibrosis Management

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Recruiting Phase 2 Interventional Study
Cystic Fibrosis CFTR Gene Mutation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
33 (estimated)
Sponsor
Arcturus Therapeutics, Inc. · Industry
Who this trial is looking for

This trial is looking for adults with cystic fibrosis who cannot take a specific type of treatment called CFTR modulators. Participants will receive the experimental treatment ARCT-032 and will help researchers examine its safety and effects.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with cystic fibrosis
  • I have not taken CFTR modulators for at least 60 days
  • I have a lung function score between 40% and 100%
  • I have a lung function score between 45% and 90% if in a specific group

You may not be able to join if

  • I have a medical condition that could increase my risk
  • I have had significant bleeding from my lungs recently
  • I have had major surgery recently
  • I have received an organ transplant
  • I need extra oxygen while awake or more than 2L while sleeping
  • I take high doses of steroids or specific oral medications
  • My liver or kidney function is not healthy according to lab tests

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Trial Locations

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: 1. Confirmed diagnosis of Cystic Fibrosis 2. Not eligible for CFTR modulator therapy or not taking CFTR modulators for at least 60 days prior to dosing (e.g. due to intolerance, poor response, or lack of access to modulators) 3. FEV1 between 40% to 100% (cohorts 1-3) and 45%…
Contacts

Clinical Trial Disclosure Manager Central Email Box

858-900-2660

CFclinicaltrials@arcturusrx.com

CONTACT

NCT ID: NCT06747858 Source: ClinicalTrials.gov